| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 40.0 | 14.3 |
| Profit before tax | 14.9 | -8.7 |
| Net income | 14.2 | -7.3 |
| EPS (diluted, $ a share) | $0.70 | $-0.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +180.5% |
|---|---|
| Operating margin | 32.0% |
10-Q filed with the SEC, NASDAQ: KROS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Keros Therapeutics, Inc.: key numbers
- Share price
- $10.03Close, Nov 16
- Market cap
- $197M
- Shares outstanding
- 19.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Keros Therapeutics, Inc.
All →Keros Therapeutics Announces $5M Stock Buyback
Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.
- Value
- $5M
Keros Therapeutics Investor Presentation
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. The presentation highlights the company's clinical pipeline, including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes.
Keros Therapeutics Financial Results
Keros Therapeutics reported third quarter 2026 financial results, highlighted by a net income of $14.2 million compared to a net loss in the prior year, primarily due to revenue recognition from its license agreement with Takeda. The company also announced the first patient dosed in its Phase 2 trial of rinvatercept for DMD and expects its $259.5 million cash balance to fund operations into the second half of 2028.
“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients. We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”
Jasbir S. Seehra, Ph.D., President and Chief Executive Officer
Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M
Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.
- Value
- $20M
- Counterparty
- Takeda Pharmaceuticals U.S.A., Inc.
Keros Therapeutics Clinical Trial Data
Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.